SCHEMBL669979

SCHEMBL669979

CCO[Si](CCCn1cc[n+](C)c1)(OCC)OCC

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.54
MEN1 O00255 2/20 0.54
HSP90AA1 P07900 2/20 0.54
KMT2A Q03164 2/20 0.54
APAF1 O14727 1/20 0.54
NPC1 O15118 1/20 0.54
PLA2G1B P04054 1/20 0.54
MAPT P10636 1/20 0.54
MAPK1 P28482 1/20 0.54
HTT P42858 1/20 0.54
RAB9A P51151 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
ATG4B Q9Y4P1 1/20 0.54
FDPS P14324 2/20 0.31
PON1 P27169 1/20 0.31
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL508922 0.98 MEN1 (0.53) SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1
Hydrochloric Acid SCHEMBL6284737 0.94 MEN1 (0.55) SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1
Hypophosphorous Acid SCHEMBL31296548 0.92 MEN1 (0.47) SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1
Hydrochloric Acid SCHEMBL18335597 0.89 SMN1; SMN2 (0.47) SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1
SCHEMBL18335678 0.84 MEN1 (0.44) SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1
SCHEMBL537081 0.83 SMN1; SMN2 (0.53) SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1
Hydrochloric Acid SCHEMBL503460 0.82 SMN1; SMN2 (0.51) SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1
Iodide SCHEMBL3733345 0.82 SMN1; SMN2 (0.51) SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1
Hydrochloric Acid SCHEMBL503472 0.78 SMN1; SMN2 (0.42) SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1
Hydrochloric Acid SCHEMBL6286595 0.78 MEN1 (0.41) SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4692215-A1 MODIFIED POLYOLEFIN RESIN COMPOSITION AND USE FOR SAID RESIN COMPOSITION TOYOBO MC Corporation (JP) 2026-02-11 EP disclosed
WO-2024203664-A1 MODIFIED POLYOLEFIN RESIN COMPOSITION AND USE FOR SAID RESIN COMPOSITION 東洋紡エムシー株式会社 2024-10-03 WO disclosed
WO-2024106024-A1 TEMPERATURE-RESPONSIVE IONIC LIQUID, TRANSDERMAL ABSORPTION ENHANCING AGENT OR TRANSDERMAL ABSORPTION-ENHANCING AID INCLUDING TEMPERATURE-RESPONSIVE IONIC LIQUID, AND PHARMACEUTICAL COMPOSITION INCLUDING TEMPERATURE-RESPONSIVE IONIC LIQUID 東レ株式会社 2024-05-23 WO disclosed
US-20240058452-A1 PHARMACEUTICAL COMPOSITION CONTAINING TEMPERATURE-RESPONSIVE IONIC LIQUID TORAY INDUSTRIES, INC. (JP) 2024-02-22 US disclosed
CN-114502142-B Pharmaceutical composition comprising temperature responsive ionic liquid 东丽株式会社 2023-05-09 CN disclosed
CN-114502142-A Pharmaceutical compositions comprising temperature-responsive ionic liquids 东丽株式会社 2022-05-13 CN disclosed
WO-2021070893-A1 PHARMACEUTICAL COMPOSITION INCLUDING TEMPERATURE-RESPONSIVE IONIC LIQUID 東レ株式会社 2021-04-15 WO disclosed
US-10850485-B2 Polyester resin composition and production method thereof TORAY INDUSTRIES, INC. (JP) 2020-12-01 US disclosed
EP-3284786-B1 POLYESTER RESIN COMPOSITION AND METHOD OF MANUFACTURING SAME TORAY INDUSTRIES (JP) 2020-09-23 EP disclosed
US-20180126714-A1 POLYESTER RESIN COMPOSITION AND PRODUCTION METHOD THEREOF TORAY INDUSTRIES, INC. (JP) 2018-05-10 US disclosed
EP-3284786-A1 POLYESTER RESIN COMPOSITION AND METHOD OF MANUFACTURING SAME Toray Industries, Inc. (JP) 2018-02-21 EP disclosed
US-20160118637-A1 POWER STORAGE DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD (JP) 2016-04-28 US disclosed
EP-2598637-A1 HETEROGENEOUS ENZYMATIC CATALYST, PROCESS FOR PREPARING SAME AND USE FOR CONTINOUS FLOW ENZYMATIC CATALYSIS Université Pierre et Marie Curie Paris 6 (FR) 2013-06-05 EP disclosed
EP-2451949-A1 HETEROGENOUS ENZYMATIC CATALYST, PREPARATION METHOD, AND USE Universite Pierre Et Marie Curie - Paris 6 (FR) 2012-05-16 EP disclosed
WO-2012022882-A1 HETEROGENEOUS ENZYMATIC CATALYST, PROCESS FOR PREPARING SAME AND USE FOR CONTINOUS FLOW ENZYMATIC CATALYSIS UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2012-02-23 WO disclosed
WO-2011004111-A1 HETEROGENOUS ENZYMATIC CATALYST, PREPARATION METHOD, AND USE UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) 2011-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240058452-A1 PHARMACEUTICAL COMPOSITION CONTAINING TEMPERATURE-RESPONSIVE IONIC LIQUID SULT1A1, CYP2C19, SULT2A1 SMN1; SMN2 1970/4885MEN1 3927/4885HSP90AA1 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.